Phase II Trial of Bevacizumab Monotherapy in Pancreatic Neuroendocrine Tumors

Conclusions Bevacizumab demonstrated promising antitumor activity in progressive PNETs comparable to standard targeted therapy. Although this study failed to reject the null hypothesis (RR, 10%), bevacizumab seems a reasonable monotherapy and a potential component of combination therapies given clinical activity and low rates of adverse events.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research